gUTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. **05900010AA**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

PTO

j. 🛛

Abstract of the Disclosure

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450 U.S. PTC 88413

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled: TREATMENT USING DANTROLENE and invented by: David Anderson, Benjamin Cameransi, Jr., and Vincent M. Conklin If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: □ Continuation □ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Which is a: ☐ Continuation □ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Which is a: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Enclosed are: **Application Elements** ☐ Filing fee as calculated and transmitted as described below Specification having pages and including the following: Descriptive Title of the Invention Cross References to Related Applications (if applicable) c. 🔲 Statement Regarding Federally-sponsored Research/Development (if applicable) d. 🔲 Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix \boxtimes Background of the Invention f. 🗵 Brief Summary of the Invention g. 🔲 Brief Description of the Drawings (if filed) h. 🛛 **Detailed Description** i. 🛛 Claim(s) as Classified Below

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 0590010AA

Total Pages in this Submission

Application Elements (Continued)

3.		Drawing(s) (when necessary as prescribed by 35 USC 113)
	a.	□ Formal Number of Sheets
	b.	☐ Informal Number of Sheets
4.	\boxtimes	Oath or Declaration
	a.	☐ Newly executed (original or copy) ☐ Unexecuted
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
	C.	☑ With Power of Attorney ☐ Without Power of Attorney
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7.		Application Data Sheet (See 37 CFR 1.76)
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
	a.	☐ Computer Readable Form (CFR)
	b.	☐ Specification Sequence Listing on:
		i. CD-ROM or CD-R (2 copies); or
		ii. 🔲 Paper
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy
		Accompanying Application Parts
9.		Assignment Papers (cover sheet & document(s))
10.		37 CFR 3.73(B) Statement (when there is an assignee)
11.		English Translation Document (if applicable)
12.		Information Disclosure Statement/PTO-1449
13.		Preliminary Amendment
14.	\boxtimes	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.		Certificate of Mailing
		☐ First Class ☐ Express Mail (Specify Label No.): Hand Delivered

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 05900010AA

Total Pages in this Submission

		Accompanying Application Parts (Continued)
17.	×	Applicant claims small entity status. See 37 CFR 1.27.
		☐ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:
18.		Additional Enclosures (please identify below):
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
19.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 05900010AA

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee **Total Claims** 82 - 20 = 62 \$9.00 \$558.00 Indep. Claims 10 - 3 = 7 \$43.00 \$301.00 х Multiple Dependent Claims (check if applicable) \$0.00 **BASIC FEE** \$385.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$1,244.00 ☐ A check in the amount of to cover the filing fee is enclosed. ☐ The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of as filing fee. ☐ Credit any overpayment. ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Dated: March 1, 2004 Signature Michael E. Whitham Reg. No. 32,635 Whitham, Curtis & Christofferson, P.C. 11491 Sunset Hills Road, Suite 340 Reston, VA 20190 CC:

(703) 787-9400

Customer Number 30743